Table 2.
Association of BCR with clinicopathological characteristics and expression of BMP-2 in 90 patients treated with radical prostatectomy for prostate cancer.
| Variable | BCR group | p-value | |
|---|---|---|---|
| No BCR (N = 54) | BCR (N = 36) | ||
| Mean age, years ± S.D | 62.35 ± 6.78 | 63.11 ± 5.48 | 0.576 |
| Mean PSA ± S.D | 8.18 ± 5.74 | 10.43 ± 6.00 | 0.078 |
| Pathological tumour stage, n (%) | 0.005 | ||
| ≤pT2c | 50 (92.6%) | 25 (69.4%) | |
| >pT2c | 4 (7.4%) | 11 (30.6%) | |
| PSM | 2 (3.7%) | 4 (11.1%) | 0.171 |
| Gleason score, n (%) | 0.032 | ||
| 6 | 22 (40.7%) | 6 (16.7%) | |
| 7 | 29 (53.7%) | 25 (69.4%) | |
| ≥8 | 3 (5.6%) | 5 (13.9%) | |
| BMP-2 expression, n (%) | 0.043 | ||
| High | 9 (16.7%) | 8 (22.2%) | |
| Moderate | 31 (57.4%) | 10 (27.8%) | |
| Weak | 11 (20.4%) | 15 (41.7%) | |
| Absent | 3 (5.6%) | 3 (8.3%) | |
S.D = standard deviation; BMP = bone morphogenetic proteins; PSA = prostate specific antigen; BCR = biochemical recurrence; PSM = post-operative surgical margin.